Product
Depemokimab
Aliases
Depemokimab (GSK3511294)
5 clinical trials
4 indications
Indication
Nasal PolypsIndication
Churg-Strauss SyndromeIndication
AsthmaIndication
Hypereosinophilic SyndromeClinical trial
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis)Status: Active (not recruiting), Estimated PCD: 2024-07-09
Clinical trial
A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) TherapyStatus: Recruiting, Estimated PCD: 2025-10-10
Clinical trial
An Open-Label, Randomized, Single-Dose, Multicenter, Parallel-Group Study to Compare the Pharmacokinetics of Subcutaneous Depemokimab When Delivered With a Safety Syringe Device or an Autoinjector in Healthy Adult ParticipantsStatus: Active (not recruiting), Estimated PCD: 2024-01-26
Clinical trial
A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-1 (depemokimAb iN CHrOnic Rhinosinusitis)Status: Active (not recruiting), Estimated PCD: 2024-08-05
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)Status: Recruiting, Estimated PCD: 2026-02-26